Search

Search Results

• MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

  Ibrahim C. Haznedaroglu

  e2014009

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.009

  3634

  PDF: 1369

  HTML: 9146

  Untitled: 241

  Untitled: 138

  Untitled: 135

  Untitled: 132

  Untitled: 149

  Untitled: 295

• DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia

  Buket Altinok Gunes, Yalda Hekmatshoar, Tulin Ozkan, Sureyya Bozkurt, O.Sena Aydos, Yahya Buyukasik, Elifcan Aladag, Asuman Sunguroglu

  e2023008

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.008

  1113

  PDF: 1075

  HTML: 400

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277391

  PDF: 1699

  HTML: 3815

• SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

  Massimo Breccia, Giuliana Alimena

  e2014003

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.003

  2894

  PDF: 1133

  HTML: 3437

• TYROSINE KINASE INHIBITORS AND INTERFERON

  Maria Dimou, Panagiotis Panagiotidis

  e2014006

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.006

  2730

  PDF: 1356

  HTML: 3024

  Cover Letter: 164

• TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti

  e2014005

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.005

  3105

  PDF: 1386

  HTML: 3961

• IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

  Tomasz Sacha

  e2014007

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.007

  4256

  PDF: 2576

  HTML: 2184

• TYROSINE KINASE INHIBITORS AND PREGNANCY

  Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti

  e2014028

  2014-04-07

  https://doi.org/10.4084/mjhid.2014.028

  3285

  PDF: 1498

  HTML: 2637

• PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

  matteo molica, elisabetta abruzzese, massimo breccia

  e2020062

  2020-09-12

  https://doi.org/10.4084/mjhid.2020.062

  2942

  PDF: 1369

  HTML: 423

• NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms

  Gianfranco Catalano, Pasquale Niscola, Cristina Banella, Daniela Diverio, Malgorzata Monika Trawinska , Stefano Fratoni, Rita Iazzoni, Paolo de Fabritiis, Elisabetta abruzzese, Nelida Ines Noguera

  e2020083

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.083

  1379

  PDF: 1068

  HTML: 160

• Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

  Nathalia Sena de Oliveira Silva, Gislaine Duarte, Samuel de Souza Medina, Guilherme Brasil Duffles Amarante, Carmino Antonio de Souza, Katia Borgia Barbosa Pagnano

  e2026001

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.001

  174

  PDF: 127

  Html: 7

• Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

  Massimo Breccia, Gioia Colafigli, Luisa Quattrocchi, elisabetta abruzzese, giuliana alimena

  e2016016

  2016-02-20

  https://doi.org/10.4084/mjhid.2016.016

  2784

  PDF: 635

  HTML: 1899

  figure 1: 135

  figure 2: 143

• Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review

  Domenico Santorsola, Elisabetta Abruzzese

  e2015020

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.020

  1867

  PDF: 1126

  HTML: 1601

• OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

  Mohamed Amine BEKADJA

  e2017062

  2017-10-25

  https://doi.org/10.4084/mjhid.2017.062

  2619

  PDF: 655

  HTML: 865

• BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

  Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

  e2024070

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.070

  1419

  PDF: 947

  HTML: 89